ReviewSeminars in immunopathology2013
Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside.
Review in Seminars in immunopathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Quantitative assessment of the effect of glutathione S-transferase genes GSTM1 and GSTT1 on hepatocellular carcinoma risk.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Pooled it
- Co-targeting p53-R249S and CDK4 synergistically suppresses survival of hepatocellular carcinoma cells.Cancer biology & therapy · 2020Article
- Profile of HBV Integration in the Plasma DNA of Hepatocellular Carcinoma Patients.Current genomics · 2019Article
- Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma.The open virology journal · 2018Review
- Ultrasound Elastography Used for Preventive Non-Invasive Screening in Early Detection of Liver Fibrosis.Journal of clinical medicine research · 2016Article
- Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals.World journal of gastroenterology · 2015Review
- Role of genetic polymorphisms in hepatitis C virus chronic infection.World journal of clinical cases · 2015Article
- HCV NS5A Up-Regulates COX-2 Expression via IL-8-Mediated Activation of the ERK/JNK MAPK Pathway.PloS one · 2015Article
- The role of cirrhosis in the etiology of hepatocellular carcinoma.Journal of gastrointestinal cancer · 2014Review
- Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection.World journal of gastroenterology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and seventh in women, accounting for 7 % of all cancers, and the third cause of cancer-related death worldwide. Nearly 90 to 95 % of all HCC occur in the context of known and often preventable risk factors, such as chronic viral hepatitis, alcohol abuse, and metabolic disorders. Although several experimental lines of research support a direct role for hepatitis C virus (HCV) in cancer promotion, cirrhosis is the main risk factor for this tumor, whereas other factors like alcohol and tobacco smoking are clearly able to accelerate HCC development. For this reason, cirrhotic patients with chronic HCV infection are subjected to abdominal ultrasound surveillance every 6 months, aimed at an early diagnosis of HCC to allow curative treatment options. Current strategies to positively impact on HCC incidence rates in HCV patients include prevention of cirrhosis development by avoiding metabolic, pharmacological, or social factors associated with accelerated progression of liver disease, or through virus eradication by interferon-based treatments. Moreover, a successful antiviral treatment has the added benefit of positively impacting on the rate of HCC development also in patients who are already cirrhotic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.